JPRN-UMIN000001685已完成2 期
Randomized phase II study of gemcitabine and S-1 combination therapy versus S-1 in advanced biliary tract cancer. (JCOG 0805) - Randomized phase II study of gemcitabine and S-1 combination therapy versus S-1 in advanced biliary tract cancer. (JCOG 0805)
Japan Clinical Oncology Group(JCOG)0 个研究点目标入组 100 人开始时间: 2009年2月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Simultaneous or metachronous (within 5 years) double cancers, with the exception of intramucosal tumor curable with local therapy 2) Pregnant or lactating women or women of childbearing potential and men who want to get partner pregnant 3) Psychosis 4) Patients requiring systemic steroids medication 5) Interstitial pneumonia or fibroid lung 6) Watery diarrhea 7) Active bacterial or fungous infection 8) Severe complication 9) Patients requiring the administration of flucytosine, phenytoin or warfarin potassium 10) Patients who can' t receive neither iodic drug nor gadolinium because of drug allergy
研究者
相似试验
已完成
2 期
Phase II study of gemcitabine alone in locally advanced pancreatic cancer: Japan Clinical Oncology Group Study (JCOG 0506)pancreatic neoplasmJPRN-C000000308Japan Clinical Oncology Group(JCOG)50
已完成
2 期
Randomized phase II study of two induction treatments of melphalan, prednisolone, plus bortezomib, JCOG-MPB versus modified PETHEMA-MPB, in elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma(JCOG1105, IMPROVE-MPB study)Elderly patients or non-elderly patients refusing transplant with untreated symptomatic myelomaJPRN-UMIN000011180Japan Clinical Oncology Group (JCOG)91
已完成
2 期
Randomized phase II study of the Induction Chemotherapy with Docetaxel alone vs CDDP+Docetaxel for c-stage IB-II Non-Small Cell Lung Cancer (JCOG 0204-MF)JPRN-C000000032Japan Clinical Oncology Group(JCOG)80
已完成
2 期
Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP)JPRN-UMIN000005342Japan Clinical Oncology Group (JCOG)80
已完成
2 期
Phase II study of Amrubicin in patients with Small-Cell Lung Cancer that is refractory or relapsed within 90 days of completing previous treatment (JCOG0901)Refractory relpased small-cell lung cancerJPRN-UMIN000002763Japan Clinical Oncology Group(JCOG)80